Health agencies' credibility at risk after week of blunders
Companies, agencies, institutions, etc
AP
the Food and Drug Administration
the Centers for Disease Control and Prevention
Trump
FDA
CDC
the U.S. Department of Health and Human Services
White House
COVID-19
Harvard University
The American Medical Association
AMA
why.”HHS
Trump and Health and Human Services
the Mayo Clinic
Goodman
Georgetown University
the National Institutes of Health
the New York Times
the White House
@AP_FDAwriter___The Associated Press Health and Science Department
the Howard Hughes Medical Institute’s Department of Science Education
People
Donald Trump
Daniel Levinson
Stephen Hahn
Daniel Carpenter
Susan Bailey
Michael Caputo
Alex Azar
Jesse Goodman
Luciana Borio
Matthew Perrone
Groups
Americans
Physical locations
No matching tags
Places
No matching tags
Locations
WASHINGTON
U.S.
Events
No matching tags
Summary
WASHINGTON (AP) — The credibility of two of the nation’s leading public health agencies is under fire this week after controversial decisions that outside experts say smack of political pressure from President Donald Trump as he attempts to move past the devastating toll of the coronavirus ahead of the November election.The head of the Food and Drug Administration grossly misstated, then corrected, claims about the life-saving power of a plasma therapy for COVID-19 authorized by his agency last Sunday. Outside experts said that flies in the face of the scientific consensus that wide-scale testing is needed to stamp out new infections.On Monday, FDA Commissioner Stephen Hahn was forced to apologize for using an erroneous, misleading statistic describing the effectiveness of a blood plasma therapy granted emergency use for COVID-19, as Trump twisted the facts and inflated the significance of the move.“He hurt his own credibility, he hurt that of his agency and he probably hurt the credibility of the next vaccine that will get approved,” said Daniel Carpenter, a Harvard University professor of government.The U.S. has invested billions of dollars in efforts to quickly develop multiple vaccines against COVID-19.
As said here by MATTHEW PERRONE and RICARDO ALONSO-ZALDIVAR